This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.
Age ≥18 years old
History of myocardial infarction
Have received coronary interventional therapy
There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% )
Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months
Previously received coronary artery bypass grafting
Stroke occurred within the previous 3 months
Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction < 35%